Malignant Bladder Neoplasm — Trials

Malignant Bladder Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,510 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 346
Recruiting: 177
Ph III recruiting: 23
Growth YoY: +17.9%
Industry share: 21%
Top sponsor: National Cancer Institute (NCI)
Termination share: 31.3%
Trials / 1,000 deaths: 20 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (179)

clinicaltrialsPublishedShowing 51–100 of 483 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03047213	Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations	active not recruiting	Phase 2	17	National Cancer Institute (NCI)NIH	1	Jul 31, 2026	clinicaltrials
NCT03237780	Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer	active not recruiting	Phase 2	72	National Cancer Institute (NCI)NIH	1	Jul 31, 2026